Comparison of Treatment Outcomes in Patients with Rectal Cancer
Comparison of Treatment Outcomes in Patients with Rectal Cancer
Objective: The aim of the present study is to evaluate survival results and acute chemoradiotherapy toxicity in patients with rectalcancer who underwent preoperative chemoradiotherapy (CRT), postoperative CRT, and non-operative CRT.Methods: The records of 139 patients with rectal cancer were analyzed retrospectively. Out of these, the data 9 (6%) patients whodied during or immediately after treatment and 2 (1%) patients who gave up the treatment were not used in the survival analysis.Results: Postoperative CRT was applied to 57 (44%) patients, preoperative CRT to 47 (37%) patients, and non-operative CRT to 24(19%) patients. Non-operative CRT group was the oldest patient group (median age: 70). There was a difference between the treatment groups regarding tumor localization (p
___
- 1. Haggar FA, Boushey RP . Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22: 191-7. [CrossRef]
- 2. Gunderson Leonard and Tepper JE. Clinical Radiation Oncology. 4th ed. Elsevier Publishers, 2015.
- 3. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444–50. [CrossRef]
- 4. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358: 1291-304. [CrossRef]
- 5. Pasetto LM, Pucciarelli S, Agostini M, Rossi E, Monfardini S. Neoadjuvant treatment for locally advanced rectal carcinoma. Crit Rev Oncol Hematol 2004; 52: 61-71. [CrossRef]
- 6. Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, et al. Postoperative radiation therapy for rectal cancer: Results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80: 21-9. [CrossRef]
- 7. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: A review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol 1988; 13: 245-52. [CrossRef]
- 8. Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008; 26: 3687-94. [CrossRef]
- 9. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, et al. Enhanced tumoricidal effct of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005; 23: 5620-7. [CrossRef]
- 10. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomized study. Lancet Oncol 2014; 15: 184- 90. [CrossRef]
- 11. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent florouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-5. [CrossRef]
- 12. Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009; 27: 5124-30. [CrossRef]
- 13. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N England J Med 2004; 351: 1731-40. [CrossRef]
- 14. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of German CAO/ARO/AIO-94 phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-33. [CrossRef]
- 15. Demircioglu F, Diclehan K. Radiation therapy schedule for rectal cancer. Turkish Journal of Oncology 2014; 29: 57-66. [CrossRef]
- 16. Glynne-Jones R, Sebag-Montefire D. Chemoradiation schedules what radiotherapy?. Eur J Cancer 2002; 38: 258-69. [CrossRef]
- 17. Sebag-Montefire D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomized trial. Lancet 2009; 373: 811-20. [CrossRef]
- 18. Schaffr M, Thoma M, Wilkowski R, Schaffr P, Dühmke E. Radio-chemotherapy as a preoperative treatment for advanced rectal cancer. Evaluation of down-staging and morbidity. Onckologie 2002; 25: 352-6. [CrossRef]
- 19. Wheeler JM, Dodds E, Warren BF, Cunningham C, George BD, Jones AC, et al. Preoperative chemoradiotherapy and total mesorectal exicision surgery for locally advanced rectal cancer: coorrelation with rectal cancer regression grade. Dis Colon Rectum 2004; 47: 2025-31. [CrossRef]
- 20. Grann A, Minsky BD, Cohen AM, Saltz L, Guillem JG, Paty PB, et al. Preliminary results of preoperative 5-florouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum 1997; 40: 515-22. [CrossRef]
- 21. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005; 241: 829-36. [CrossRef]
- 22. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4. [CrossRef]
- 23. RTOG/EORTC Late Radiation Morbidity Scoring Schema. Available from: URL: https://www.rtog.org/ (cited 2017 february 21).
- 24. Meterissian S, Skibber J, Rich T, Roubein L, Ajani J, Cleary K, et al. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol 1994; 1: 111-6. [CrossRef]
- 25. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: longterm results. Ann Surg 2004; 240: 711-8. [CrossRef]
- 26. Habr-Gama A, Sabbaga J, Gama-Rodrigues J, São Julião GP, Proscurshim I, Bailão Aguilar P, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum 2013; 56: 1109-17. [CrossRef]
- 27. Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016; 17: 174-83. [CrossRef]
- 28. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effctive surgical adjuvant therapy for high-risk rectal carcinoma. N Eng J Med 1991; 324: 709-15. [CrossRef]
- 29. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Eng J Med 1985; 312: 1465-72. [CrossRef]
- 30. Hyams DM, Mamounas EP, Petrelli N, Rockette H, Jones J, Wieand HS, et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997; 40: 131-9. [CrossRef]
- 31. Park JH, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer 2011; 117: 3703-12. [CrossRef]